Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection

[1]  Leslie Cope,et al.  Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. , 2014, American journal of clinical pathology.

[2]  Lianhua Dong,et al.  Erratum to: Evaluation of droplet digital PCR for characterizing plasmid reference material used for quantifying ammonia oxidizers and denitrifiers , 2014, Analytical and Bioanalytical Chemistry.

[3]  Lianhua Dong,et al.  Evaluation of droplet digital PCR for characterizing plasmid reference material used for quantifying ammonia oxidizers and denitrifiers , 2014, Analytical and Bioanalytical Chemistry.

[4]  P. Laurent-Puig,et al.  Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. , 2013, Clinical chemistry.

[5]  Helene Myrtue Nielsen,et al.  Sensitive Detection of KRAS Mutations Using Enhanced‐ice‐COLD‐PCR Mutation Enrichment and Direct Sequence Identification , 2013, Human mutation.

[6]  J. Pagès,et al.  Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  V. Moreno,et al.  Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer. , 2012, Clinical chemistry.

[8]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[9]  D. Ahlquist,et al.  Stool DNA testing for the detection of pancreatic cancer , 2012, Cancer.

[10]  O. Basturk,et al.  Large duct type invasive adenocarcinoma of the pancreas with microcystic and papillary patterns: a potential microscopic mimic of non-invasive ductal neoplasia , 2012, Modern Pathology.

[11]  K. Kinzler,et al.  Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. , 2012, Gastroenterology.

[12]  Renzo Boldorini,et al.  Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer , 2011, Clinical Cancer Research.

[13]  D. Ahlquist,et al.  Stool DNA Testing for the Detection of Pancreatic Cancer: Identification and Assessment of Methylation Marker Candidates , 2011 .

[14]  I. Dahabreh,et al.  All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. , 2011, Cancer treatment reviews.

[15]  Anton I. Petrov,et al.  WebFR3D—a server for finding, aligning and analyzing recurrent RNA 3D motifs , 2011, Nucleic Acids Res..

[16]  Jin Li,et al.  Ice-COLD-PCR enables rapid amplification and robust enrichment for low-abundance unknown DNA mutations , 2010, Nucleic Acids Res..

[17]  M. Ilyas,et al.  Comparative analysis of pyrosequencing and QMC‐PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection , 2010, International journal of experimental pathology.

[18]  G. Makrigiorgos,et al.  COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. , 2009, Biochemical Society transactions.

[19]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[20]  R. Schwenzer,et al.  Implementation of a robotized real-time PCR setup for the use of the Quantifiler™ Human DNA Quantification Kit , 2008 .

[21]  R. Bernards,et al.  Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.

[22]  C. Sawyers.  The cancer biomarker problem , 2008, Nature.

[23]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Burczynski,et al.  Analytical validation of genotyping assays in the biomarker laboratory. , 2007, Pharmacogenomics.

[26]  Silvia Benvenuti,et al.  Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.

[27]  A. Russo,et al.  Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  V. Agnese,et al.  Prognostic and predictive factors in colorectal cancer : Kirsten Ras in CRC ( RASCAL ) and TP 53 CRC collaborative studies , 2005 .

[29]  J. Herman,et al.  K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Hruban,et al.  Genetic progression in the pancreatic ducts. , 2000, The American journal of pathology.